TABLE 1—
Country | Screening Method | Carrier Prevalence (Hb S Trait and Hb C Trait), % | Gene Frequencies | Sickle Cell Disease Incidence | |
Guadeloupe | Universal screening from 1984 | 10.5 | βS 0.042–βC 0.013 | 1/304 | |
Martinique | Universal screening from 1984 | 10.0 | βS 0.040–βC 0.012 | 1/300 | |
French Guyana | Universal screening from 1992 | 10.0 | βS 0.039–βC 0.012 | 1/235 | |
Jamaica | Screening in the southeast, southern, and western regional health authorities from 1995 | 15.0 | βS 0.055–βC 0.019 | 1/150 | |
Cuba | Prenatal diagnosis from 1982 | 3.1 | βS 0.011a–βC 0.0036a
βS 0.053b–βC 0.006b |
NA | |
Barbados | 997 consecutive births (1995) | 4.0 (estimated) | NA | 1/497 | |
NBS implemented by CAREST associated with the SickKids Caribbean Initiative | |||||
Tobago | Universal screening from 2008 | 12.9 | βS 0.098–βC 0.036 | 1/238 | |
Grenada | Universal screening from 2014 | ||||
Saint Lucia | Move toward universal screening from 2015 | ||||
Jamaica | Universal screening in all public hospitals as of December 2015c |
Note. CAREST = Caribbean Network of Researchers on Sickle Cell Disease and Thalassemia; Hb = Hemoglobin; NA = not available; NBS = newborn screening. Information was partly obtained from a workshop carried out in April 2006 in Guadeloupe by health professional from Bahamas, Barbados, Cuba, Dominica, Guadeloupe, French Guyana, Haiti, Jamaica, Martinique, Dominican Republic, and Trinidad and Tobago.5–8
Figures for western side of Cuba.
Figures for eastern side of Cuba.
In collaboration with Ministry of Health and Sickle Cell Trust.